BISPHOSPHONATES IN THE TREATMENT OF OSTEOPOROSIS. EFFICACY AND SAFETY OF IBANDRONATE


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Osteoporosis (OP) - is a common noncommunicable disease with such threatening complication as bone fractures leading to disability, a significant reduction in quality of life, and high mortality. The article presents data from international clinical studies on the efficacy and tolerability of third-generation nitrogen-containing bisphosphonate - Ibandronate (Bonviva) - in female patients with OP. A modern integrated approach to the treatment of OP, both pharmacological and non-drug methods of therapy, as well as ways to assessment of the clinical efficacy of drug therapy of OP.

Толық мәтін

Рұқсат жабық

Авторлар туралы

M. Telnova

FSBEI HE "First MSMU n.a. I.M. Sechenov" of RMH

Department of Endocrinology IPGE Moscow

N. Petunina

FSBEI HE "First MSMU n.a. I.M. Sechenov" of RMH

Email: napetunina@mail.ru
MD, Prof., Head of the Department of Endocrinology IPGE Moscow

Әдебиет тізімі

  1. Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я.: Остеопороз - от редкого симптома эндокринных болезней до безмолвной эпидемии XX-XXI веков. Проблемы Эндокринологии. 2011;57:35-45.
  2. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 1993;94(6):646-50.
  3. Михайлов Е.Е., Беневоленская Л.И. Руководство по остеопорозу. М., 2003.
  4. Лесняк О.М., Ершова О.Б. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии 2010. Naturaprint. 2011.
  5. World Health Organization. Prevention and management of osteoporosis, report of Global Health Risks: mortality and burden of WHO scientific group. WHO Technical Reports Series 921. Geneva: WHO. 2003.
  6. Остеопороз: Диагностика, профилактика и лечение (клинические рекомендации) / Под ред. Л.И. Беневоленской, О.М. Лесняк. М., 2005. 176 с.
  7. Boonen S., Bischoff-Ferrari H., Cooper C., Lips P., Ljunggren O., Meunier P.J., Reginster J.Y. Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence. Calcified Tissue International. 2006;78(5):257-70.
  8. Body J., Bergmann P., Boonen S., Boutsen Y., Devogelaer J.P., Goemaere S., Kaufman J.M., Rozenberg S., Reginster J.Y. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporosis International. 2010;21(10):1657-80.
  9. Эндокринология: национальное руководство / Под ред. И.И. Дедова, Г.А. Мельниченко. М., 2016. 1112 с.: ил.
  10. European Medicines Agency: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013.
  11. European Medicines Agency: Questions and answers on the review of Protelos 6 and Osseor (strontium ranelate) 15 March 2012 EMA/18304/2012.
  12. Дедов И.И., Рожинская Л.Я., Белая Ж.Е. Роль и место бисфосфонатов в профилактике и лечении остеопороза. 10-летний опыт применения алендроната. Остеопороз и остеопатии. 2005;1:20-30.
  13. Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А. Ибандронат (Бонвива) - новое направление в лечении бисфосфонатами. Лучшая приверженность лечению - лучший результат. Остеопороз и остеопатии. 2006;3:23-9.
  14. Белая Ж.Е., Рожинская Л.Я. Бисфосфонаты в терапии постменопаузального остеопороза. Доктор Ру. 2010;58(7):29-38.
  15. Верткин А.Л., Наумов А.В. Остеопороз. М., 2015.
  16. Бартл Р. Остеопороз. Профилактика, диагностика, лечение. М., 2012.
  17. Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., Christiansen C., Rowell L., Mairon N., Bonvoisin B., Drezner M.K., Emkey R., Felsenberg D., Cooper C., Delmas P.D., Miller P.D. Effects and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann. Rheum. Dis. 2006; 65:654-61.
  18. Emkey R., Koltun W., Beusterien K., Seidman L., Kivitz A., Devas V., Masanauskaite D. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr. Med. Res. Opin. 2005;21(12): 1895-903.
  19. Rossini M., Orsolini G., Adami S., Kunnathully V., Gatti D. Osteoporosis treatment: why ibandronic acid? Expert Opin. Pharmacoter. 2013; 14(10):1371-81.
  20. Recker R., Weinstein R., Chesnut C.H., et al. Long-term treatment with oral daily and intermittent ibandronate produces newly formed bone of normal quality in patients with postmenopausal osteoporosis. Osteoporos. Int. 2003;14(Suppl. 7):S73.
  21. Chesnut C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 2004;19(8):1241-49.
  22. Campbel M.J., Machin D. Medical Statistis a commonsense approach. 2003. P. 62-3.
  23. Miller P.D., Ragi-Eis S., Mautalen C., Ramirez F., Jonkanski I. Effects invenous ibandronate injections on renal function in women with postmenopausal osteoporosis at high risk for renal disease - the DIVINE study. Bone. 2011;49:1317-22.
  24. Ettinger M.P., Felsenberg D., Harris S.T., Wasnich R., Skag A., Hiltbrunner V., Wilson K., Schimmer R.C., Miller P.D. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J. Rheumatol. 2005;32(10):1968-74.
  25. Miller P.D., McClung M., Macovei I., Stakkestad J.A., Luckey M., Bonvoisin B., Reginster J.Y., Recker R.R., Hughes C., Lewiecki E.M., Felsenberg D., Delmas P.D., Kendler D.L., Bolognese M.A., Mairon N., Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone Miner. Res. 2005;20:1315-22.
  26. Pyon E.Y. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin. Ther. 2006;28(4): 475-90.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>